You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
億帆醫藥(002019.SZ):控股子公司在研產品F-652中國II期臨牀試驗結果達到預期目標
格隆匯 12-21 19:23

格隆匯12月21日丨億帆醫藥(002019.SZ)公佈,公司控股子公司億一生物醫藥開發(上海)有限公司(簡稱“上海億一”)於2023年12月21日完成在研品種重組人白介素22-Fc融合蛋白(簡稱“F-652”)在中國開展的適應症為慢加急性肝衰竭(簡稱“ACLF”)的II期《臨牀試驗總結報吿》,根據臨牀試驗數據結果分析,證明F-652在乙肝併發ACLF的病人中安全性和PK/PD特徵良好,同時也顯示了F-652能產生比現有治療手段更顯著或者更重要臨牀療效的趨勢。這標誌着上海億一自主研發的F-652在慢加急性肝衰竭中國II期臨牀試驗結果達到預期目標。

本次臨牀試驗中劑量探索研究證明F-652在乙肝併發慢加急性肝衰竭的中國病人中安全性和PK/PD特徵良好,同時也顯示了F-652能產生比現有治療手段更顯著或者更重要臨牀療效的趨勢。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account